Literature DB >> 6306432

Glucocorticoids increase GTP-dependent adenylate cyclase activity in cultured fibroblasts.

G S Johnson, C J Jaworski.   

Abstract

Glucocorticoid treatment of cultured fibroblasts increases intracellular cyclic AMP accumulation induced by isoproterenol or cholera toxin. This increase in agonist activity is not a direct action of glucocorticoids on cyclic AMP metabolism since about 2 days are necessary for maximal effect. Basal cyclic AMP levels are not changed. In membrane preparations, GTP-dependent adenylate cyclase activity is increased, basal adenylate cyclase activity is unchanged, and NaF-stimulated activity is decreased. The number of beta-adrenergic receptors is unchanged, but the affinity of receptor for the antagonist dihydroalprenolol is increased about 3-fold. This change in affinity is probably not responsible for the increased response to isoproterenol since the augmented response is noted at 0.1 mM isoproterenol, a concentration much larger than the apparent KD (about 5 nM). The results suggest that an alteration in some component in the GTP-dependent regulatory complex is responsible for the increase in agonist response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306432

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  3 in total

1.  Dexamethasone enhances the effects of parathyroid hormone on human periodontal ligament cells in vitro.

Authors:  R M Nohutcu; M J Somerman; L K McCauley
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

2.  Corticosterone differentially regulates the expression of Gs alpha and Gi alpha messenger RNA and protein in rat cerebral cortex.

Authors:  N Saito; X Guitart; M Hayward; J F Tallman; R S Duman; E J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Beta-adrenergic signalling in neoplastic lung type 2 cells: glucocorticoid-dependent and -independent defects.

Authors:  K A Droms
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.